Dosing with Enbrel® can be individualised based on the needs of each patient.1
The recommended dose of Enbrel® for paediatric patients with plaque PsO is based on weight1:
Treatment should be discontinued in paediatric patients with PsO who show no response after 12 weeks. If re-treatment with Enbrel® is indicated, the above guidance on dosage and treatment duration should be followed.1
Enbrel® Significantly Improves Clinical Outcomes in Pediatric Patients With Plaque PsO2,3
Enbrel® Improves the severity of plaque PsO in children and adolescents as early as Week 2.2
Adapted from Paller AS, et al. 2008.
Paller AS. 2008. Methods: In this 48-week study, 211 patients with PsO (4-17 years of age) were initially randomly assigned to a double-blind trial of 12 QW subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram of body weight (to a maximum of 50 mg), followed by 24 weeks of QW open-label etanercept. At Week 36, 138 patients underwent a second randomisation to placebo or etanercept to investigate the effects of withdrawal and retreatment. The primary endpoint was 75% or greater improvement from baseline in the PASI 75 at Week 12. Secondary endpoints included PASI 50, PASI 90, PGA of clear or almost clear of disease and safety assessments.
Enbrel® Helps Paediatric Patients With Plaque PsO Achieve Sustained Clinical Response3
PASI 50, PASI 75* and PASI* 90 responses compared with baseline throughout first 96 weeks of extension study (observed cases)3
Adapted from Paller AS, et al. 2010.
Paller AS. 2010: Methods: Patients who completed or received substantial treatment benefit in a 48-week, randomised, double-blind, placebo-controlled study (N=211) evaluating the efficacy and safety of QW etanercept (0.8 mg/kg) were enrolled in this 264-week OLE study.2
The primary endpoint was the occurrence of AEs. Secondary endpoints included PASI 50%, 75% and 90% responses compared with baseline; static PGA; and clear and clear/almost clear static PGA status. Results from a 96-week interim analysis are presented.2
PASI 75* at Week 96 (61%) was similar to the report at Week 12 for patients initially randomised to Enbrel® in the Paller clinical trial (57%)3
*Improvements in PASI 75, 50 and 90 over baseline in PASI.3
AE, adverse event; OLE, open-label extension; PASI, Psoriasis Area and Severity Index; PGA, physician global assessment; PsO, psoriasis; QW, once a week; TNFR, tumour necrosis factor receptor.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
Enbrel® is a soluble tumour necrosis factor receptor fusion protein
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.